ADU-S100
As of the edition of 20 October 2026, ADU-S100 is a drug: stopped in 2021; acts on STING1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2021
- Kind
- Unknown
- Registered trials
- 3, 3 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of ADU-S100.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| STING1 | Stimulator of interferon genes protein | Q86WV6 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 0 | 0 | 2 |
| Phase 2 | 1 | 0 | 0 | 1 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Chinook Therapeutics | Lead sponsor of trials | 2016 to now |
| Novartis | Lead sponsor of trials | 2017 to now |